Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.0%

21 terminated/withdrawn out of 191 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

10%

20 trials in Phase 3/4

Results Transparency

21%

13 of 63 completed trials have results

Key Signals

26 recruiting13 with results13 terminated8 withdrawn

Enrollment Performance

Analytics

N/A

76(50.3%)

Phase 2

40(26.5%)

Phase 3

19(12.6%)

Phase 1

13(8.6%)

Early Phase 1

2(1.3%)

Phase 4

1(0.7%)

151Total

N/A(76)

Phase 2(40)

Phase 3(19)

Phase 1(13)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (191)

Showing 20 of 191 trials

NCT04610372Not ApplicableRecruiting

5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)

Role: lead

NCT06835725Phase 2Recruiting

Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer

Role: lead

NCT03862911Not ApplicableActive Not Recruiting

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer

Role: lead

NCT05023265Not ApplicableRecruiting

Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT

Role: collaborator

NCT04185389Completed

Long-Term Follow-Up of HPV FOCAL Participants

Role: collaborator

NCT07295171Not ApplicableRecruiting

HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG

Role: lead

NCT06819969Recruiting

The Canadian Lung Outcomes in Users of Vaping Devices Study

Role: collaborator

NCT03694015Not ApplicableTerminated

SUPR-3D: Simple Unplanned Palliative Radiotherapy Versus 3D Conformal Radiotherapy for Patients With Bone Metastases

Role: lead

NCT03033914Phase 1Active Not Recruiting

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Role: collaborator

NCT05576831Not ApplicableRecruiting

STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision

Role: lead

NCT03246802Not ApplicableRecruiting

Partial Prostate Salvage High Dose Rate Brachytherapy

Role: lead

NCT02297672Not ApplicableActive Not Recruiting

Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed Implant

Role: lead

NCT06200974Recruiting

Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer

Role: lead

NCT03426748Not ApplicableActive Not Recruiting

LDR vs. HDR Brachytherapy for Prostate Cancer

Role: lead

NCT01936883Not ApplicableActive Not Recruiting

Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR Brachytherapy

Role: lead

NCT07346053Phase 3Not Yet Recruiting

The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer

Role: collaborator

NCT06574620Not ApplicableRecruiting

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

Role: lead

NCT04261972Active Not Recruiting

Cell-free DNA in Hereditary And High-Risk Malignancies 1

Role: collaborator

NCT07338981Phase 3Not Yet Recruiting

The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

Role: collaborator

NCT05570994Phase 1Enrolling By Invitation

177Lu-HTK03170 in mCRPC With PSMA Positive Disease

Role: lead